Another gene with a 2.2-fold expression rise is Slc45a3, a well-known marker of prostate cancer progression, whose loss determines poorer prognosis for cancer patients (Perner et al., 2013; Hernández-Llodrà et al. 2017; Pin et al., 2017). This evidence concerns the gene SLC45A3 and prostate cancer.